Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.

Pituitary - 1 Jun 2014

Athanasoulia A P, Sievers C, Uhr M, Ising M, Stalla G K, Schneider H J

Abstract excerpt

Treatment with dopamine agonists in patients with prolactinomas has been associated with weight loss in short term studies. However, long-term studies on weight changes are lacking. Taq1A is a restriction fragment length polymorphism considered as a gene marker for the DRD2 gene. The presence of at least one A1 allele is linked to reduced brain dopaminergic activity due to reduced receptor binding and lower...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Body Mass Index
Share to Dopamine Agonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pituitary Neoplasms

Share to Protein Serine-Threonine Kinases

Share to Receptors, Dopamine D2

Share to Weight Loss

Share to Young Adult

Source

Identifiers

PMID: 23740147
DOI: 10.1007/s11102-013-0496-y

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.PMID 23740147Read ↗

Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?Semantic proximity Read ↗

TaqIA polymorphism in dopamine D2 receptor gene complicates weight maintenance in younger obese patients.Semantic proximity Read ↗

Association analyses for dopamine receptor gene polymorphisms and weight status in a longitudinal analysis in obese children before and after lifestyle intervention.Semantic proximity Read ↗

Reward Deficiency Syndrome in Children: Obesity and Metabolic Disorders are Associated with the SNP TaqIA C32806T of the DRD2 GeneSemantic proximity Read ↗

Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.Semantic proximity Read ↗

Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.Semantic proximity Read ↗

Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study.Semantic proximity Read ↗

Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.Semantic proximity Read ↗

Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.Semantic proximity Read ↗

The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.Semantic proximity Read ↗

Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.Semantic proximity Read ↗

D2 dopamine receptor (DRD2) gene Taq1A polymorphism and the eating-related psychological traits in eating disorders (anorexia nervosa and bulimia) and obesity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.